EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Ovid Therapeutics's enterprise value is €127.89 Mil.
Ovid Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was €0.44 Mil. Therefore, Ovid Therapeutics's EV-to-Revenue for today is 292.64.
The historical rank and industry rank for Ovid Therapeutics's EV-to-Revenue or its related term are showing as below:
FRA:1OT'
s EV-to-Revenue Range Over the Past 10 Years
Min: -19.65 Med: 12.29 Max: 1314.74
Current: 291.72
During the past 9 years, the highest EV-to-Revenue of Ovid Therapeutics was 1314.74. The lowest was -19.65. And the median was 12.29.
FRA:1OT's EV-to-Revenue is ranked worse than 90.47% of 1039
companies
in the Biotechnology industry
Industry Median: 8.18
vs FRA:1OT: 291.72
The historical data trend for Ovid Therapeutics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Ovid Therapeutics's EV-to-Revenue
For the Biotechnology subindustry, Ovid Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ovid Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ovid Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Ovid Therapeutics's EV-to-Revenue falls into.
Ovid Therapeutics's current Enterprise Value is €127.89 Mil.
Ovid Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.44 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ovid Therapeutics's share price for today is €2.74.
Ovid Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ovid Therapeutics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Ovid Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class or best-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:1OT has been successfully added to your 